Gold prices slip after rallying on Powell rate cut talk
Investing.com -- Shares of Coloplast (CSE:COLOb) climbed 3.5% as the medical device company reported first-quarter revenue in line with consensus expectations and earnings per share (EPS) that surpassed forecasts.
The growth in Voice & Respiratory segments exceeded projections, although Continence Care faced challenges in Emerging Markets, and Interventional Urology was affected by a product recall expected to continue into the second quarter.
The Danish healthcare company announced that its EBIT before special items for the first quarter slightly outperformed consensus expectations, with a margin improvement of 16 basis points compared to consensus and 11 basis points compared to RBC estimates. Adjusted net income and EPS also exceeded expectations, with EPS coming in 7.7% higher than consensus and 7.8% higher than RBC estimates, attributed to lower than anticipated finance charges.
An extraordinary expense related to the transfer of intellectual property from Iceland to Denmark resulted in an effective tax rate of 41% for the quarter. This transfer will affect cash flows in FY2026/27 but will be compensated by reduced tax payments in Denmark starting FY2024/25. This extraordinary tax charge had been previously indicated by the company but was not reflected in the consensus compiled by the company.
Looking ahead, Coloplast reiterated its fiscal year 2024/25 guidance of 8-9% organic growth, aligning with consensus estimates of 8.3%, and a neutral foreign exchange impact, slightly more conservative than the consensus of a 0.2% positive impact.
However, the company now anticipates a roughly 1.5% growth headwind from the divestment of its Skin Care division, resulting in expected reported growth of about 7%, slightly below the consensus estimate of 7.2%. The EBIT margin forecast before special items remains "around" 28%, in line with a consensus of 28.1%, assuming benefits from lower inflation on input costs and profitability improvements in Advanced Wound Care.
The expected capital expenditure is around DKK 1.4 billion, and the ordinary tax rate is projected to be about 22%, but the effective tax rate is estimated to be around 40% due to the extraordinary tax impact from the Kerecis IP transfer.
RBC analysts commented on the results, saying, "We expect investors to be reassured by today’s results, with revenue growth and profitability in line with expectations de-risking forecasts for the full year." This sentiment reflects the company’s solid performance and the market’s positive reaction to the first-quarter results.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.